UPDATED: Sofinnova hauls in $548M to build and scale startups — as European VCs step up their biopharma game
When Sofinnova Partners unveiled its $540 million crossover fund earlier this year, the Paris-based power VC player touted its leading role in providing late-stage capital to high-growth startups in Europe and beyond.
But that doesn’t mean it’s forgetting its roots in early-stage healthcare investing.
In fact, the Sofinnova crew was already talking to investors behind the scenes for what would become the largest iteration yet of its flagship fund. At $548 million (€472 million), Sofinnova Capital X is almost $50 million bigger than its predecessor and brings its total assets under management to more than €2.5 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,500+ biopharma pros reading Endpoints daily — and it's free.